Article | December 3, 2018

Evolution of Single-Use Bioprocessing Into BioPharm 4.0

Source: Cytiva

By Michelle Stafford, Pete Genest, and Randal Goomer, Ph.D.

GE Healthcare Life Sciences Uses Data Analytics to Drive Continuous Improvements in Efficiency

The biologic drug market is projected to reach $390 billion within the next two years,1and the need for efficiency and speed may be outpacing the market. The advent of personalized medicine requires smaller batch sizes, while new drug modalities and new production technologies emphasize the need for adaptable manufacturing environments.

Biopharmaceutical manufacturers are seeking dynamic processing economics that address the paradigm shift from blockbuster drugs with established, large-batch production schemes to small-scale manufacturing and innovative technologies.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: